Texas Technology Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Texas Technology Digest.

Press releases published on September 28, 2026

NEMI Names Kevin Flick CFO to Accelerate AI Adoption in the Physical Economy
CiraSync Named a 2026 Industry Icon in Enterprise Technology & SaaS
USZIPCodeMap.com Adds One-click Text Copying to it's ZIP Radius Tool
Exdion Insurance Advances Purpose-Built AI with Proposal Builder, Transforming Insurance Proposal Creation
enQase Appoints Ann Dunkin to Federal Market Sector Board
Innovorbs Technologies Launches Agentic AI Solutions for Autonomous, Self-Healing Enterprise IT Operations
Innovorbs Technologies Expands Cisco, HPE, and Arista Network Engineering With Hardware Refresh and 24/7 Operations
Austin Mayor Kirk Watson and The University of Texas at Austin's TACC Back Occam Foundry Quantum Technology Campus
INNOVOTEX Expands Macrocycle Drug Conjugate Platform via Dual-Payload Technology for Tumor-Selective Combination Therapy
Currus Biologics announces FDA IND clearance for Phase 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours
Crusoe Developing Data Center Campus in Armstrong County, Texas
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency
IDT Corporation Reports Record Fourth Quarter and Fiscal Year 2026 Results
Waldencast plc Announces First Half 2026 Financial Results
Exascale Labs Holdings Inc. Reports 111% Revenue Growth for Full Fiscal Year 2026 and Provides Business Update Following Successful Nasdaq Listing
Natural Alternatives International, Inc. Announces Fiscal 2026 Q4 and YTD Results
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
Applied Digital Sets Fiscal First Quarter 2027 Conference Call for Wednesday, October 7, 2026, at 5:00 p.m. Eastern Time
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
AI/R Compass UOL leva ao AWS Marketplace solução de IA que habilita empresas a acelerar a saída de mainframe

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Texas Technology Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.